ATC/DDD classification

Transcription

1 The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measurin unit are tools for exchanin and comparin data on dru use at international, national or local levels. The ATC/DDD system has become the old standard for international dru utilization research. It is maintained by the WHO Collaboratin Centre for Dru Statistics Methodoloy in Oslo, Norway. Visit for more information. (temporary) The followin s and DDDs were areed at the meetin of the WHO International Workin Group for Dru Statistics Methodoloy in March Comments or objections to the decisions from the meetin should be forwarded to the WHO Collaboratin Centre for Dru Statistics Methodoloy before 1 September If no objections are received before this date, the new s and DDDs will be considered final and included in the January 2019 version of the ATC/DDD Index. New ATC 5 th level codes abemaciclib aniotensin II apalutamide avatrombopa candesartan, amlodipine and hydrochlorothiazide cannabidiol cefpodoxime and beta-lactamase inhibitor copanlisib doravirine edaravone fexinidazole fostamatinib emiliptin and rosuvastatin hydroen peroxide ibalizumab lamivudine, tenofovir disoproxil and doravirine leuprorelin and bicalutamide metformin, saxaliptin and dapaliflozin L01XE50 C01CX09 L02BB05 B02BX08 C09DX06 N03AX24 J01DD64 L01XX61 J05AG06 N07XX14 P01CA03 B02BX09 A10BH52 D11AX25 J05AX23 J05AR24 L02AE51 A10BD25 276

2 Temporary New ATC 5 th level codes (continued) omidenepa prasterone talazoparib telotristat trifarotene S01EX06 G03XX01 L01XX60 A16AX15 D10AD06 New ATC level codes (other than 5 th levels) Other sex hormones and modulators of the enital system G03XX Chane of Previous New dimethyl fumarate N07XX09 L04AX07 Chanes of ATC level names Previous New Aniotensin II antaonists, plain Aniotensin II receptor blockers (ARBs), plain C09C Aniotensin II antaonists, plain Aniotensin II receptor blockers (ARBs), plain C09CA Aniotensin II antaonists, Aniotensin II receptor blockers (ARBs), combinations combinations C09D Aniotensin II antaonists and Aniotensin II receptor blockers (ARBs) diuretics and diuretics C09DA Aniotensin II antaonists and Aniotensin II receptor blockers (ARBs) calcium channel blockers and calcium channel blockers C09DB Aniotensin II antaonists, other Aniotensin II receptor blockers (ARBs), combinations other combinations C09DX fluoromethylcholine (18F) fluorocholine (18F) V09IX07 combinations potassium (different salts in combination) A12BA30 New DDDs DDD unit Adm.R* artemether 0.28 R P01BE02 artesunate 0.28 R P01BE03 benralizumab 0.54 m P R03DX10 chenodeoxycholic acid 1 O A05AA01 cladribine 0.34 m O L04AA40 dupilumab 21.4 m P D11AH05 277

3 Temporary New DDDs (continued) DDD unit Adm.R* emicizumab 15 m P B02BX06 ertuliflozin 10 m O A10BK04 uselkumab 1.79 m P L04AC16 letermovir 0.48 O,P J05AX18 ocrelizumab 3.29 m P L04AA36 patiromer calcium 8.4 O V03AE09 rolapitant 0.18 O A04AD14 telotristat 0.75 O A16AX15 * Administration Route: O = oral; P = parenteral. Chanes of DDDs Previous DDD New DDD DDD Unit Adm.R.* DDD Unit Adm.R.* aprepitant 1 95 m P 150 m P A04AD12 aprepitant 95 m O 165 m O A04AD12 temocillin 2 P 4 P J01CA17 vasopressin (aripressin) 4 U P 40 U P H01BA01 * Administration Route: P = parenteral. 1 expressed as fosaprepitant WHO Collaboratin Centre for Dru Statistics Methodoloy Oslo, May

4 (final) The followin s and DDDs were areed at the meetin of the WHO International Workin Group for Dru Statistics Methodoloy in October These are considered final and included in the January 2019 version of the ATC/DDD Index. New ATC 5 th level codes ambrisentan and tadalafil atazanavir and ritonavir atezolizumab avelumab caplacizumab cefteram cladribine 1 clenbuterol and ambroxol crisaborole crofelemer cytarabine and daunorubicin dacomitinib dapivirine delafloxacin doxepin emapalumab enasidenib encorafenib enisamium iodide epacadostat eravacycline ertuliflozin fexapotide floxuridine alcanezumab lecaprevir and pibrentasvir ibandronic acid and colecalciferol icotinib imidazolyl ethanamide pentandioic acid indocyanine reen ipraliflozin isoniazid, sulfamethoxazole, trimethoprim and pyridoxine kaocel lanadelumab C02KX52 J05AR23 L01XC32 L01XC31 B01AX07 J01DD18 L04AA40 R03CC63 D11AH06 A07XA06 L01XY01 L01XE47 G01AX17 J01MA23 D04AX01 L04AA39 L01XX59 L01XE46 J05AX17 L01XX58 J01AA13 A10BK04 G04CX04 L01BC09 N02CX08 J05AP57 M05BB09 L01XE48 J05AX21 V04CX01 A10BK05 J04AM08 J05AX22 B06AC05 279

5 Final New ATC 5 th level codes (continued) letermovir lorlatinib lusutrombopa medroxyproesterone and estradiol meropenem and vaborbactam metformin and ertuliflozin naldemedine neratinib norestimate and ethinylestradiol ozanimod patisiran peramivir riboflavin rifampicin, ethambutol and isoniazid roxadustat sitaliptin and ertuliflozin tebipenem pivoxil tildrakizumab tilorone tosufloxacin uramustine vainal rin with proestoen valbenazine valsartan and nebivolol J05AX18 L01XE44 B02BX07 G03AA17 J01DH52 A10BD23 A06AH05 L01XE45 G03AB09 L04AA38 N07XX12 J05AH03 S01XA26 J04AM07 B03XA05 A10BD24 J01DH06 L04AC17 J05AX19 J01MA22 L01AD08 G02BB02 N07XX13 C09DX05 1 Oral formulations indicated for multiple sclerosis. Parenteral formulations are classified in L01BB04. Chane of ATC level name Previous New dinutuximab dinutuximab beta L01XC16 New DDDs DDD Unit Adm.R* atazanavir and ritonavir O J05AR23 baricitinib 4 m O L04AA37 cariprazine 3 m O N05AX15 cefroxadine 2.1 O J01DB11 cefteram 0.4 O J01DD18 ceftriaxone and beta-lactamase inhibitor 2 2 P J01DD63 colistin 9 MU O A07AA10 280

6 Final New DDDs (continued) DDD Unit Adm.R* delafloxacin delafloxacin O P J01MA23 J01MA23 delamanid 0.2 O J04AK06 desfesoterodine 3.5 m O G04BD13 droxidopa 1 O C01CA27 eluxadoline 0.2 O A07DA06 enisamium iodide 1.5 O J05AX17 estradiol 1.53 m TD spray G03CA03 faropenem 0.75 O J01DI03 follitropin delta 12 mc P G03GA10 arenoxacin 0.4 O J01MA19 emifloxacin 0.32 O J01MA15 imidazolyl ethanamide pentandioic acid 90 m O J05AX21 insulin larine and lixisenatide 40 U 3 P A10AE54 kaocel 60 m O J05AX22 kanamycin 3 O A07AA08 lomefloxacin 0.4 O J01MA07 mepyramine theophyllinacetate 0.6 O R03DA12 midecamycin 1.2 O J01FA03 misoprostol 0.2 m O G02AD06 naldemedine 0.2 m O A06AH05 nusinersen 0.1 m P M09AX07 pyrimethamine, combinations 75 m 4 P P01BD51 reslizumab 7.1 m P R03DX08 rimantadine 0.2 O J05AC02 sarilumab 14.3 m P L04AC14 secnidazole 2 O P01AB07 tebipenem pivoxil 0.56 O J01DH06 thyroid land preparations 0.1 O H03AA05 tilorone O J05AX19 tosufloxacin 0.45 O J01MA22 * Administration Route: O = oral; P = parenteral. 1 refers to atazanavir. 2 refers to ceftriaxone. 3 refers to insulin larine. 4 refers to pyrimethamine. 281

7 Final Chanes of DDDs Previous DDD New DDD DDD Unit Adm.R.* DDD Unit Adm.R.* amoxicillin amoxicillin 1 1 O P O P J01CA04 J01CA04 amoxicillin and betalactamase inhibitor 1 1 O 1.5 O J01CR02 ampicillin 2 P 6 P J01CA01 cefepime 2 P 4 P J01DE01 ciprofloxacin 0.5 P 0.8 P J01MA02 colistin 3 MU P 9 MU P J01XB01 meropenem 2 P 3 P J01DH02 * Administration Route: O = oral; P = parenteral. 1 New ATC level name valid from WHO Collaboratin Centre for Dru Statistics Methodoloy Oslo, May